ELOXX PHARMACEUTICALS INC
ELOXNASDAQTrading Snapshot
- Day Range
- $15.23 – $15.55
- 52-Week Range
- $0.00 – $23.40
- Volume
- $2.80B
- Avg Volume
- $2.73B
- Shares Outstanding
- 4.0M
- Next Earnings
- Dec 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $160,000
- Last Q Revenue
- $41,431
- P/E Ratio
- —
- P/S Ratio
- 379.2x
- EPS (TTM)
- $-7.06
- Dividend Yield
- —
- Dilution (1yr)
- +38.5%
Why Investors Own ELOX
- ✓High-growth profile — revenue up +42.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ELOXX PHARMACEUTICALS INC
ELOX
StockOtter · stockotter.spaceAbout ELOXX PHARMACEUTICALS INC
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Head to Head Comparison: Eloxx Pharmaceuticals (NASDAQ:ELOX) & LENZ Therapeutics (NASDAQ:LENZ)
LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) and Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companie
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027 ARLINGTON, Mass., Sept. 11, 2026 /PRN
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonse